bullish
Terumo Corp (4543 JP): A COVID Recovery Play; Cardiac & Vascular Business to Drive Multi-Year Growth
Tina has highlighted this Insight as a Top Pick
407 Views26 Jul 2022 20:38
SUMMARY
- Terumo Corp (4543 JP) earns 56% revenue from cardiac and vascular segment, which is the fastest growing segment of the company. The segment is seeing continued recovery from COVID impact.
- For FY23, Terumo guided for cardiac and vascular segment revenue of ¥445.5B (+12% y/y) and adjusted operating profit of ¥113.4B (+22% y/y), leading to operating margin of 25.5% (+200bps y/y).
- Over the next five years, Terumo aims for high single-digit revenue growth from the segment, through new product launches and expanding adoption of existing products across disease areas.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Terumo Corp (4543 JP): Strong C&V Business Momentum Continues; Profitability to Improve in FY2425 Jul 2023
- Terumo Corp (4543 JP): Sequential Decline Expected in Q4; Stronger Yen to Weigh on Performance28 Mar 2023
- Terumo Corp (4543 JP): H1FY23 Results Reflect Continued Recovery from the Pandemic14 Dec 2022
- Terumo Corp (4543 JP): A COVID Recovery Play; Cardiac & Vascular Business to Drive Multi-Year Growth26 Jul 2022
- Japan's Governance: Growth Policy and Corporate Governance of Terumo Corporation (4543)08 Nov 2021
- Japan's Governance: Retirement of Treasury Stock and Performance, Corporate Governance04 Nov 2021
x